Search This Blog

Thursday, January 2, 2020

Judge blocks California law on dialysis clinics

A federal judge on Monday blocked enforcement of a California law aimed at preventing increased billing costs at dialysis clinics.
There is “a dire public interest” in granting a preliminary injunction that would bar enforcement for months while a lawsuit against it proceeds through the courts, Judge David O. Carter said.
If Assembly Bill 290 is permitted to take effect before it is reviewed, “thousands of California HIPP recipients—who number among the poorest and most medically vulnerable of all Californians—may not be able to afford the dialysis treatments that keep them alive (or may be forced to dedicate all of their scant financial resources to medical care) and may face further delays in receiving a transplant,” Carter wrote.
HIPP refers to the Health Insurance Premium Program run by the not-for-profit American Kidney Fund. The program, paid for by dialysis clinics, covers insurance premiums for low-income patients with kidney disease who need dialysis.
California passed the law this year in an effort to deter dialysis clinics from encouraging patients to enroll in health plans that give them higher reimbursement rates.
But the lawsuit contends the law will force the American Kidney Fund to close down the program, which helps about 3,700 patients in the state.
The fund has said the law creates requirements in California that conflict with federal laws the program must follow.
State lawmakers contended that two large dialysis clinics in California were contributing to the fund’s program, which in turn covered their patients’ premiums with private insurers that paid higher reimbursement rates back to the clinics.
The state passed the law after a ballot measure to cap dialysis clinics’ profits failed in 2018.

Vaping-Associated Lung Injury Riskier for Older Patients

Patients who were rehospitalized or who died after being treated for EVALI (e-cigarette or vaping product use–associated lung injury) were more likely to have been older and to have had at least one chronic illness, the Centers for Disease Control and Prevention (CDC) reports.
In response to these findings, the CDC has issued interim guidance recommending confirmation of patients’ medical stability for 24 to 48 hours prior to discharge, outpatient follow-up of patients within 48 hours after discharge, and follow-up with a pulmonologist within 2 to 4 weeks after discharge.
According to the CDC, 2561 cases of EVALI and 55 deaths have been reported as of January 2, 2020, and numbers continue to rise.
These findings underscore the need for incorporating measures that “might minimize EVALI patients’ risk for rehospitalization and death, especially among patients with chronic conditions,” the authors write.
Christina A. Mikosz, MD, and colleagues from the CDC’s Lung Injury Response Epidemiology/Surveillance Task Force partnered with state health departments to develop a voluntary reporting service to collect data “on confirmed and probable hospitalized or deceased EVALI patients.”
Using data reported to the CDC as of December 10, 2019, they compared the clinical characteristics of patients with EVALI who were rehospitalized or died after hospital discharge with those of patients with EVALI who were neither rehospitalized nor died after hospital discharge (comparator group). The findings were published online January 2 in Morbidity and Mortality Weekly Report.
Data from 2409 cases that required hospitalization were evaluated, including 52 deaths. The researchers found that among the 1139 patients discharged before October 31, 2019, 31 (2.7%) were rehospitalized, and seven (13.5%) died following discharge. The median interval from discharge to readmission and from discharge to death was 4 days and 3 days, respectively. The comparator group included 768 patients with EVALI who were also discharged before October 31, 2019, but who were not rehospitalized and who did not die.
Mikosz and colleagues found that 70.6% of those who were rehospitalized and 83.3% of those who died had one or more chronic conditions, compared with 25.6% of patients in the comparator group. Chronic conditions included cardiac disease, chronic pulmonary disease (eg, chronic obstructive pulmonary disease and obstructive sleep apnea), and diabetes.
Further, patients who died following their initial visit were more likely to be older (median age, 54 years). All required intubation and mechanical ventilation during their initial hospital visit. Duration of initial hospitalization and use of corticosteroids or antibiotics were similar for all three groups.
Given that most rehospitalizations occurred within 2 to 4 days following initial discharge, the authors suggest “that ensuring clinical stability before discharge as well as postdischarge follow-up optimally within 48 hours might minimize risk for rehospitalization and death, especially among patients with chronic conditions.”
Findings Prompt New Guidance
In response to the finding by Mikosz and colleagues, the CDC, in consultation with the Lung Injury Response Clinical Working Group, has provided updated interim guidance for the management of patients with EVALI. These new recommendations include the following:
  • Confirmation of stable vital signs for at least 24 to 48 hours prior to discharge;
  • Follow-up within 48 hours of discharge (previous recommendation was within 2 weeks of discharge);
  • Focused management of comorbidities and coordination of posthospitalization specialty care; and
  • Ensuring access to mental and behavioral health services post discharge.
The authors have disclosed no relevant financial relationships.
MMWR. Published online January 2, 2019. Full text

Alzheimer’s Brain Atrophy Predicted by Tau PET Scan

Tau tangles predicted the location of brain atrophy in people with mild Alzheimer’s disease a year in advance, a small longitudinal imaging study showed.
Baseline tau PET patterns in people with early symptomatic Alzheimer’s predicted how much neurodegeneration would occur a median of 15 months later, reported Renaud La Joie, PhD, of the University of California San Francisco (UCSF), and co-authors.
Tau PET also predicted the spatial distribution of atrophy in the following year, they wrote in Science Translational Medicine.
The match between baseline tau and subsequent neurodegeneration patterns was “remarkably predictive, not only at the group level, but at the individual patient level,” noted co-author Gil Rabinovici, MD, also of UCSF.
“You could predict where atrophy would occur from patient to patient in a very specific way,” he told MedPage Today. “We think this provides evidence that tau is actually spreading upstream of neurodegeneration and a major driver of Alzheimer’s disease.”
The study involved 32 patients in early clinical stages of Alzheimer’s disease who had mild cognitive impairment or mild dementia and a positive amyloid-beta scan. All patients had structural MRI and positron emission tomography (PET) with Pittsburgh compound B to determine amyloid and flortaucipir to assess tau at the baseline visit and a second MRI at follow-up a median of 15 months later. Average age was 64 at baseline; 21 participants were women and 11 were men.
At the group level, longitudinal atrophy was greater in regions that had higher baseline tau. These patients also developed more severe cortical atrophy, independent of baseline cortical thickness.
Tau patterns predicted about 40% of subsequent atrophy — “a very strong number when you’re looking at neuroimaging correlates,” Rabinovici said — and predictive value differed by age.
“Among people who had an early age of onset of Alzheimer’s disease, the predictive value of tau approached nearly 60%,” Rabinovici noted. “It may be that younger patients have a purer form of Alzheimer’s disease with less co-pathologies.”
The predictive value of amyloid was not significant at this stage of Alzheimer’s disease. “There’s obviously been a lot of focus on amyloid as the cause of Alzheimer’s disease and the primary drug target,” Rabinovici noted. “But it’s been known for several decades that the clinical symptoms of the disease correlate much more strongly with the distribution burden of neurofibrillary tangles than they do with amyloid plaques.”
“The major controversy is whether tau tangles are just representative of cell dysfunction and neuron death — are they just tombstones? — or whether they are really a driver of the disease,” he added. “With tau imaging, we can test these questions prospectively in vivo.”
Because brain atrophy is linked closely to clinical disease progression, the findings “are encouraging for the potential use of tau PET for personalized medicine approaches and for improving clinical trials,” observed Rik Ossenkoppele, PhD, of Lund University in Sweden, who wasn’t involved with the study.
“This study also emphasizes that once the symptomatic stage of Alzheimer’s disease is reached, tau pathology is a key factor involved in further disease progression, while the role of amyloid-beta at this stage seems limited,” Ossenkoppele told MedPage Today.
The study needs to be replicated in a larger sample, Rabinovici noted. Meanwhile, the researchers will follow the cognitive trajectories of these 32 patients as their Alzheimer’s disease progresses. “We’ll have to see whether these patterns translate into predicting specific cognitive changes,” he said.
“If we could provide a more accurate prognosis in both the rate of change and the quality of change, that would be very valuable to patients and families,” he pointed out. “It will also be valuable in clinical trial design. You could potentially improve your power to assess a drug’s clinical benefit by looking at individual patient trajectories, as opposed to the group level of analysis we currently do.”
Disclaimer
This study was supported by the Alzheimer’s Association, NIH’s National Institute on Aging, the Tau Consortium, and the California Department of Health Services.
Researchers reported relationships with Eli Lilly, Genentech, Merck, Biogen Idec, Bristol-Myers Squibb, ExpertConnect, Grifols, the John Douglas French Foundation, Tau Consortium, the National Institute for Health Research Cambridge Biomedical Research Centre, the American Brain Foundation, Bioclinica, Novartis Pharmaceuticals, Avid Radiopharmaceuticals, GE Healthcare, Life Molecular Imaging, Axon Neurosciences, Roche, and Eisai.

Chembio +16% as it expects FDA test approval

Chembio Diagnostics (NASDAQ:CEMI) is up 15.8% after hours following its update on an FDA submission of its DPP HIV-Syphilis test.
The company is anticipating FDA approval of the system (including the HIV-Syphilis test and DPP Micro Reader) during the first quarter, it says.
The system is a single-use 15-minute screening test using a 10-microliter fingerstick sample of whole blood, venous whole blood or plasma.
“Our clinical study, which included the prospective enrollment of over 2,500 subjects, demonstrated that the DPP HIV-Syphilis System met the performance requirements established with the FDA,” says CEO John Sperzel.

What to look for in the Fed’s FOMC minutes Friday

The Fed releases minutes from the FOMC’s December meeting tomorrow at 2PM ET.
Look for discussion about repo operations that the central bank started in September to calm the short-term funding market used by banks.
As usual, the FOMC members’ take on the economic outlook will be pored through; its December statement had removed language about risks to current economic expansion, so it will be interesting if the minutes uncover diverging views on whether global economic conditions and trade uncertainty had reduced downside risks.
Also, discussion on the Fed’s balance sheet could move markets.

Novan’s SB206 flunks late-stage molluscum studies

Thinly traded nano cap Novan (NASDAQ:NOVN) is poised for a significant down move after announcing failed results from two Phase 3 clinical trials, B-SIMPLE1 and B-SIMPLE2, evaluating topical gel SB206 for the treatment of molluscum contagiosum (MC).
Both failed to achieve the primary endpoint of complete clearance of all treatable MC at week 12. Compete results, including 24-week safety data, should be available in March.
Undeterred, the company says multiple sensitivity analyses support a path forward. It plans to use the results from B-SIMPLE2 and an additional confirmatory study, expected to start in April, as the principal data package for a U.S. marketing application targeted for Q2 2021, subject to funding and FDA feedback.
Management will host a conference call tomorrow, January 3, at 8:30 am ET to discuss the results.

Incyte’s itacitinib flunks GvHD study

Incyte (NASDAQ:INCYreports that a Phase 3 clinical trial, GRAVITAS-301 evaluating the combination of JAK1 inhibitor itacitinib and corticosteroids in patients with treatment-naïve acute graft-versus-host disease (GvHD) did not meet the primary endpoint of a statistically significant improvement in overall response rate (ORR) at Day 28 compared to placebo plus corticosteroids (74.0 percent vs. 66.4 percent, p=0.08, respectively).
There was also no difference in non-relapse mortality at month 6, a key secondary endpoint.
Results will be submitted for presentation at a future medical conference.
Management will host a conference call today at 5:00 pm ET to discuss the data.
Shares down 10% after hours.